Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by francoisl13on Nov 29, 2024 11:50am
15 Views
Post# 36337636

RE:RE:RE:New Press Release - Kane Biotech Announces Third Quarter 2024 Financial Results

RE:RE:RE:New Press Release - Kane Biotech Announces Third Quarter 2024 Financial ResultsCorrect and if I understand well, this upcoming collaboration will, again, be for DispersinB.
He also made a comment, and this is not the first time he does, about the fact that other major players in the wound care area are showing interest for DispersinB. 
Things to look for in the weeks before the Holidays (from Kane's latest presentation and video);
1. Pot'l financing...
2. Start of the ACNE trials with UofMiami;
3. First shipment of Revyve wound gel spray;
4. Sales distribution agreement for Canada;
There is also a new product on the Omni website...see the link below;
[url=https://https://www.omnibioinnovations.com/shop/uncategorized/bio-scalp-detoxifier-care-active/]OMNIInnovation scalp detoxifier[/url]
They do not mention the use of Coactiv+ on the bottle or in the description but, looks like it is their first product using KNE technology.
GLTA!
<< Previous
Bullboard Posts